Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$12.38 - $29.19 $26.9 Million - $63.3 Million
-2,169,351 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$15.07 - $21.71 $7.36 Million - $10.6 Million
-488,445 Reduced 18.38%
2,169,351 $47.1 Million
Q4 2020

Feb 16, 2021

BUY
$12.72 - $16.16 $6.78 Million - $8.62 Million
533,375 Added 25.11%
2,657,796 $40.2 Million
Q3 2020

Nov 12, 2020

BUY
$12.34 - $17.92 $2.64 Million - $3.83 Million
213,600 Added 11.18%
2,124,421 $27 Million
Q2 2020

Aug 14, 2020

BUY
$12.39 - $17.33 $5.8 Million - $8.12 Million
468,400 Added 32.47%
1,910,821 $32.7 Million
Q4 2019

Feb 13, 2020

SELL
$16.11 - $25.98 $6.83 Million - $11 Million
-423,767 Reduced 22.71%
1,442,421 $23.2 Million
Q3 2019

Nov 13, 2019

SELL
$18.28 - $26.91 $1.32 Million - $1.94 Million
-72,000 Reduced 3.71%
1,866,188 $34.1 Million
Q2 2019

Aug 16, 2019

BUY
$17.68 - $21.57 $16.9 Million - $20.6 Million
956,968 Added 97.53%
1,938,188 $41.7 Million
Q1 2019

Apr 12, 2019

BUY
$14.41 - $19.64 $2.08 Million - $2.84 Million
144,578 Added 17.28%
981,220 $19.3 Million
Q4 2018

Jan 30, 2019

BUY
$12.45 - $23.47 $3.48 Million - $6.56 Million
279,642 Added 50.21%
836,642 $10.9 Million
Q2 2018

Aug 01, 2018

BUY
$11.6 - $19.27 $4.35 Million - $7.22 Million
374,900 Added 205.88%
557,000 $10.7 Million
Q1 2018

Apr 20, 2018

BUY
$11.77 - $16.08 $942,777 - $1.29 Million
80,100 Added 78.53%
182,100 $2.25 Million
Q4 2017

Jan 22, 2018

BUY
$11.86 - $14.08 $1.21 Million - $1.44 Million
102,000
102,000 $1.25 Million

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $257M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track First Manhattan CO Portfolio

Follow First Manhattan CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

News

Stay updated on First Manhattan CO with notifications on news.